These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Non-Healing Corneal Ulcer and Uveitis Following Monkeypox Disease: Diagnostic and Therapeutic Challenges. Androudi S; Kaufman AR; Kouvalakis A; Mitsios A; Sapounas S; Al-Khatib D; Schibler M; Pineda R; Baglivo E Ocul Immunol Inflamm; 2024 Apr; 32(3):253-258. PubMed ID: 37140328 [TBL] [Abstract][Full Text] [Related]
31. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox. Mazzotta V; Cozzi-Lepri A; Lanini S; Mondi A; Carletti F; Tavelli A; Gagliardini R; Vita S; Pinnetti C; Aguglia C; Colavita F; Faccendini P; Matusali G; Faraglia F; Beccacece A; Paulicelli J; Girardi E; Nicastri E; Vaia F; Maggi F; Antinori A J Med Virol; 2023 Jun; 95(6):e28868. PubMed ID: 37306318 [TBL] [Abstract][Full Text] [Related]
32. Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System. Vo C; Zomorodi R; Silvera R; Bartram L; Lugo LA; Kojic E; Urbina A; Aberg J; Sigel K; Chasan R; Patel G Open Forum Infect Dis; 2023 Nov; 10(11):ofad552. PubMed ID: 38023539 [TBL] [Abstract][Full Text] [Related]
33. Navigating the expanded access investigational new drug protocol for tecovirimat: lessons learned from a public-private hospital partnership during the 2022 NYC mpox outbreak. Mgbako O; Chan J; Pitts RA; DiLorenzo MA; Knutsen D; Mazo D Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e110. PubMed ID: 37502253 [TBL] [Abstract][Full Text] [Related]
34. Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA. Lash MK; Latham NH; Chan PY; Foote MMK; Garcia EA; Silverstein MF; Wong M; Alexander M; Alroy KA; Bajaj L; Chen K; Howard JS; Jones LE; Lee EH; Watkins JL; McPherson TD Emerg Infect Dis; 2023 Nov; 29(11):2353-2357. PubMed ID: 37796277 [TBL] [Abstract][Full Text] [Related]
35. Addressing mpox at a Frontline Community Health Center: Lessons for the Next Outbreak. Allan-Blitz LT; Khan T; Elangovan K; Smith K; Multani A; Mayer KH Public Health Rep; 2024; 139(3):294-300. PubMed ID: 37846528 [TBL] [Abstract][Full Text] [Related]
36. Association of Tecovirimat Therapy With Mpox Symptom Improvement: A Cross-sectional Study-King County, Washington, May-October 2022. Karmarkar EN; Golden MR; Kerani RP; Pogosjans S; Chow EJ; Bender Ignacio RA; Ramchandani MS; Kay MK; Cannon CA; Dombrowski JC Open Forum Infect Dis; 2024 Mar; 11(3):ofae029. PubMed ID: 38456195 [TBL] [Abstract][Full Text] [Related]
37. Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report. Martinez AE; Frattaroli P; Vu CA; Paniagua L; Mintz J; Bravo-Gonzalez A; Zamudio P; Barco A; Rampersad A; Lichtenberger P; Gonzales-Zamora JA Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992234 [TBL] [Abstract][Full Text] [Related]
38. Countering Mpox Vaccination Disparities in Los Angeles County, California, May-December 2022. Brihn A; Yeganeh N; Kulkarni S; Moir O; Madrid S; Perez M; Singhal R; Kim AA Am J Public Health; 2023 Dec; 113(12):1258-1262. PubMed ID: 37733994 [TBL] [Abstract][Full Text] [Related]
39. Monkeypox: A re-emerging disease. Kaur N; Dabar J; Bassi P Indian J Pharmacol; 2024 Mar; 56(2):129-135. PubMed ID: 38687317 [TBL] [Abstract][Full Text] [Related]
40. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models. Cinatl J; Bechtel M; Reus P; Ott M; Rothweiler F; Michaelis M; Ciesek S; Bojkova D J Med Virol; 2024 Jan; 96(1):e29354. PubMed ID: 38180134 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]